Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-10. Numbers and descriptions here follow the published literature rather than marketing material.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Church records of christenings, marriages and burials Voter or citizenship rolls Records of wills and deceased estates Land tenure records Tax lists Muster lists for militia service The internet has stimulated amateur one-place studies, especially in England, since websites allow large volumes of historic material to be published easily. One-place studies of urban parishes are less common, since urban populations were migratory and analysis is more difficult when few of the families remain present for the whole period under study.
Beta-actin, or Actin beta (HUGO Gene Nomenclature Committee abbreviation ACTB/ACTB) is one of six different actin isoforms which have been identified in humans. This is one of the two nonmuscle cytoskeletal actins. Actins are highly conserved proteins that are involved in cell motility, structure and integrity. Alpha actins are a major constituent of the contractile apparatus.
Chronic administration of LSD has been associated with long-lasting schizophrenia-like behavioral changes in rodents, which were not blocked by serotonin 5-HT2A receptor antagonism but may instead be related to LSD's dopamine D2-like receptor agonism. Single macrodoses of LSD do not produce such changes in rodents, but the preceding findings may have implications for continuous psychedelic microdosing with LSD. LSD, via activation of serotonin 5-HT2 receptors, has been found to potentiate MDMA-induced serotonergic neurotoxicity in rodents.
== Toxicology == The toxicity of metal carbonyls is due to toxicity of carbon monoxide, the metal, and because of the volatility and instability of the complexes, any inherent toxicity of the metal is generally made much more severe due to ease of exposure. Exposure occurs by inhalation, or for liquid metal carbonyls by ingestion or due to the good fat solubility by skin resorption. Most clinical experience were gained from toxicological poisoning with nickel tetracarbonyl and iron pentacarbonyl due to their use in industry. Nickel tetracarbonyl is considered as one of the strongest inhalation poisons. Inhalation of nickel tetracarbonyl causes acute non-specific symptoms similar to a carbon monoxide poisoning, such as nausea, cough, headache, fever, and dizziness. After some time, severe pulmonary symptoms such as cough, tachycardia, and cyanosis, or problems in the gastrointestinal tract occur. In addition to pathological alterations of the lung, such as by metalation of the alveoli, damages are observed in the brain, liver, kidneys, adrenal glands, and spleen. A metal carbonyl poisoning often necessitates a lengthy recovery. Chronic exposure by inhalation of low concentrations of nickel tetracarbonyl can cause neurological symptoms such as insomnia, headaches, dizziness and memory loss. Nickel tetracarbonyl is considered carcinogenic, but it can take 20 to 30 years from the start of exposure to the clinical manifestation of cancer.
Sources: en.wikipedia.org
n → p + e− + νe. At the fundamental level (as depicted in the Feynman diagram on the right), this is caused by the conversion of the negatively charged (−1/3 e) down quark to the positively charged (+2/3 e) up quark, which is promoted by a virtual W− boson; the W− boson subsequently decays into an electron and an electron antineutrino:
=== Traumatic === Traumatic vertebral dissection may follow blunt trauma to the neck, such as in a traffic collision, direct blow to the neck, strangulation, or whiplash injury. 1–2% of those with major trauma may have an injury to the carotid or vertebral arteries. In many cases of vertebral dissection, people report recent very mild trauma to the neck or sudden neck movements, e.g. in the context of playing sports. Others report a recent infection, particularly respiratory tract infections associated with coughing. Trauma has been reported to have occurred within a month of dissection in 40% with nearly 90% of the traumas being minor. It has been difficult to prove the association of vertebral artery dissection with mild trauma and infections statistically. It is likely that many "spontaneous" cases may in fact have been caused by such relatively minor insults in someone predisposed by other structural problems to the vessels. A more likely theory, also as yet unproven, is that the low-energy traumatic dissections are actually spontaneous dissections brought to medical attention by the onset of neurological symptoms. These neurological events represent embolic phenomena due to loosening or breakdown of the clot at the site of the dissection, which can be triggered by low energy trauma or even occur spontaneously. The fragments travel within the arterial system downstream to the brain to cause stroke or stroke-like symptoms. Vertebral artery dissection has also been reported in association with some forms of neck manipulation.
Homocysteine is biosynthesized naturally via a multi-step process. First, methionine receives an adenosine group from ATP, a reaction catalyzed by S-adenosyl-methionine synthetase, to give S-adenosyl methionine (SAM). SAM is a widely used source of methyl radicals and a cofactor for radical SAM enzymes. Transfer of the methyl group to an acceptor molecule results in the formation of S-adenosyl-homocysteine. Hydrolysis of this thioether gives L-homocysteine. L-Homocysteine reacts with tetrahydrofolate (THF) to give L-methionine.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.